Kirsti Ilva

1.1k total citations
7 papers, 184 citations indexed

About

Kirsti Ilva is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Kirsti Ilva has authored 7 papers receiving a total of 184 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Rheumatology, 3 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Kirsti Ilva's work include Rheumatoid Arthritis Research and Therapies (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Kirsti Ilva is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). Kirsti Ilva collaborates with scholars based in Finland. Kirsti Ilva's co-authors include Markku Korpela, Hannu Kautiainen, Marjatta Leirisalo‐Repo, Kari Puolakka, Anna Karjalainen, Pekka Hannonen, Timo Möttönen, Reijo Luukkainen, Markku Kauppi and Harri Blåfield and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and The Journal of Rheumatology.

In The Last Decade

Kirsti Ilva

7 papers receiving 176 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kirsti Ilva Finland	7	161	68	36	25	24	7	184
Christian Høili Netherlands	5	226 1.4×	85 1.3×	20 0.6×	19 0.8×	33 1.4×	8	240
Hallvard Fremstad Netherlands	5	226 1.4×	85 1.3×	20 0.6×	19 0.8×	33 1.4×	9	241
Nobuyuki Asai Japan	10	124 0.8×	47 0.7×	22 0.6×	12 0.5×	29 1.2×	20	176
Hilde Haukeland Norway	7	248 1.5×	89 1.3×	21 0.6×	24 1.0×	34 1.4×	19	271
William Habib Chahade Brazil	4	109 0.7×	70 1.0×	24 0.7×	10 0.4×	22 0.9×	5	162
Yousra J. Dakkak Netherlands	9	234 1.5×	77 1.1×	14 0.4×	22 0.9×	38 1.6×	15	257
Jacqueline Nam United Kingdom	10	289 1.8×	85 1.3×	40 1.1×	18 0.7×	18 0.8×	22	310
Claudio Mastaglio Italy	5	138 0.9×	62 0.9×	20 0.6×	75 3.0×	14 0.6×	7	228
Leticia Garcia‐Montoya United Kingdom	10	223 1.4×	77 1.1×	25 0.7×	22 0.9×	10 0.4×	30	259
Hans Versendaal Netherlands	3	161 1.0×	42 0.6×	14 0.4×	15 0.6×	23 1.0×	4	256

Countries citing papers authored by Kirsti Ilva

Since Specialization

Citations

This map shows the geographic impact of Kirsti Ilva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirsti Ilva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirsti Ilva more than expected).

Fields of papers citing papers by Kirsti Ilva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirsti Ilva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirsti Ilva. The network helps show where Kirsti Ilva may publish in the future.

Co-authorship network of co-authors of Kirsti Ilva

This figure shows the co-authorship network connecting the top 25 collaborators of Kirsti Ilva. A scholar is included among the top collaborators of Kirsti Ilva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirsti Ilva. Kirsti Ilva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Aaltonen, Kalle, Pasi Aronen, Tuulikki Sokka, et al.. (2016). Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. Lara D. Veeken. 55(10). 1803–1811. 22 indexed citations

Puolakka, Kari, Hannu Kautiainen, Harri Blåfield, et al.. (2015). Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Scandinavian Journal of Rheumatology. 44(6). 449–455. 18 indexed citations

Rantalaiho, Vappu, Hannu Kautiainen, Markku Korpela, et al.. (2013). Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. Annals of the Rheumatic Diseases. 73(4). 788–790. 13 indexed citations

Leirisalo‐Repo, Marjatta, Hannu Kautiainen, Leena Laasonen, et al.. (2012). Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Annals of the Rheumatic Diseases. 72(6). 851–857. 69 indexed citations

Kauppi, Markku, Marko H. Neva, Kari Laiho, et al.. (2009). Rheumatoid Atlantoaxial Subluxation Can Be Prevented by Intensive Use of Traditional Disease Modifying Antirheumatic Drugs. The Journal of Rheumatology. 36(2). 273–278. 37 indexed citations

Puolakka, Kari, Hannu Kautiainen, Timo Möttönen, et al.. (2007). Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN‐RACo trial. Scandinavian Journal of Rheumatology. 36(4). 270–277. 7 indexed citations

Nordström, Dan, Liisa Konttinen, Markku Korpela, et al.. (2005). Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatology International. 26(8). 741–748. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact